{"prompt": "['Confidential', 'Prof. Dr. Kristian Reich', 'Clinical Study Protocol', 'APLANTUS 069-008', 'Final 3.0, 07. June 2018', '9', 'Selection of Patients', '9.1', 'Inclusion / Exclusion Criteria', 'The investigator must ensure that all patients who meet the following inclusion and exclusion', 'criteria are offered enrolment in the study. Patients will be enrolled if all inclusion and none of', 'the exclusion criteria are met. All patients screened to participate in the study will be', 'documented and the reason for study exclusion will be documented to avoid enrolment bias.', '9.1.1 Inclusion Criteria', 'Male and female patients aged 18 years or more at screening visit.', 'Patients with chronic PPP (disease history of at least 6 months of diagnosis), who', 'are eligible for treatment with systemic therapy defined as having PPP', 'inadequately controlled by topical treatment and / or phototherapy and / or', 'previous systemic therapy', 'Patients with chronic moderate to severe PPP defined as patients with a PPPASI', '12 with or without concomitant plaque-type psoriasis', 'Negative result of a urine pregnancy test taken at screening and at baseline for', 'all women, except those who are surgically sterile or at least 1 year', 'postmenopausal (i.e. at least 12 consecutive months with amenorrhea without', 'other known or suspected medical cause)', 'Willingness and capability of using a highly effective contraceptive measures', 'from Screening visit until the end of at least one menstrual cycle (but not less', 'than 28 days) following discontinuation of apremilast as defined below:', 'Female patient of childbearing potential (fertile, following menarche and', 'until becoming post-menopausal unless permanently sterile) using a', 'highly effective method of contraception OR female patients of non-', 'childbearing potential (surgically sterilized [e.g. hysterectomy, bilateral', 'salpingectomy and bilateral oophorectomy] or post-menopausal)', 'Male patient, and their female partner of childbearing potential, using a', 'highly effective method of contraception', 'Adequate contraceptive method defined as:', 'A method with less than 1% failure rate (e.g. permanent', 'sterilization, hormone implants, hormone injections, some', 'intrauterine devices, or vasectomized partner)', 'OR', 'The use of two methods of contraception (e.g. one barrier method', '[condom, diaphragm or cervical/vault caps] with spermicide and', 'one hormonal contraceptive [e.g. combined oral contraceptives,', 'patch, vaginal ring, injectables and implants])', 'Patient is capable of understanding and giving written, voluntary informed', 'consent before study screening.', 'Willingness and capability of complying with all study procedure requirements, as per', \"the Investigator's judgment (e.g. patient able to swallow the apremilast tablets, blood\", 'sampling).', 'Page 29 of 75']['Confidential', 'Prof. Dr. Kristian Reich', 'Clinical Study Protocol', 'APLANTUS 069-008', 'Final 3.0, 07. June 2018', '9.1.2 Exclusion Criteria', 'General', 'Pregnant or breast-feeding women.', 'Current or history of psychiatric disease that would interfere with the ability to comply', 'with the study protocol or give informed consent.', 'Patients known to have had a substance abuse (drug or alcohol) problem within', 'the previous 12 month', 'Individuals who are involved in the organization of the study', 'Patients who are in any way dependent on the investigator', 'Patients who are participating in a clinical study', 'Relatives, partner or staff of any clinical site personnel', 'Disease-related', 'Evidence of skin conditions (e.g. eczema) other than PPP / psoriasis that would', 'interfere with evaluations of the effect of study medication on PPP or psoriasis.', 'Laboratory values from routine blood test taken within the 8 weeks prior to', 'screening with any of the following:', 'Serum creatinine >1.4 X upper limit of normal (ULN) for age and gender', 'Estimated Glomerular Filtration Rate (eGFR) < 30 mL/min/1.73 m\u00b2 according', 'to the CKD-EPI equation', 'Pustular psoriasis lesions on the part of body other than hands or feet', 'Significant concurrent medical conditions at the time of screening, including:', 'Risk factors for renal toxicity (renal inflammation)', 'Severe hepatic dysfunction', 'Unstable angina pectoris', 'Uncompensated congestive heart failure', 'Severe pulmonary disease requiring hospitalization or supplemental oxygen', 'therapy', 'Immunodeficiency disorders: primary or secondary', 'Known positive HIV test result, hepatitis B surface (HBS) antigen or hepatitis', 'C (HCV) test result', 'Uncontrolled Insulin-dependent diabetes mellitus', 'Cancer or history of cancer (except for resected cutaneous basal cell or', 'squamous cell carcinoma) in the last 5 years', 'Open cutaneous ulcers', 'Any condition that, in the judgment of the investigator, might cause this study to be', 'detrimental to the patient.', 'Page 30 of 75']\n\n###\n\n", "completion": "END"}